Stock data
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB) reported net income of -US$18.86M for fiscal 2026. The figures below come from the company's SEC filings.
Annual results
Data as of 2026-06-30
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | — | — | -US$18.19M | -US$18.86M | — |
| 2025 | — | — | -US$57.28M | -US$58.92M | — |
| 2024 | — | — | -US$1.54M | -US$1.82M | — |
| 2023 | — | — | -US$1.78M | -US$2.66M | — |
| 2022 | — | — | -US$1.99M | -US$2.66M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$4.57M | — |
| 2026-03-31 | — | -US$6.36M | — |
| 2025-12-31 | — | -US$3.09M | — |
| 2025-09-30 | — | -US$4.84M | — |
| 2025-06-30 | — | -US$4.07M | — |
| 2025-03-31 | — | -US$54.07M | — |
| 2024-12-31 | — | -US$0.43M | — |
| 2024-09-30 | — | -US$0.35M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.